Tags

Type your tag names separated by a space and hit enter

Effect of growth hormone treatment on trunk fat accumulation in adult GH-deficient Japanese patients: a randomised, placebo-controlled trial.
Curr Med Res Opin. 2006 Oct; 22(10):1973-9.CM

Abstract

OBJECTIVE

Patients with growth hormone deficiency (GHD), both Japanese and Caucasian, have an abnormal body composition with pronounced abdominal obesity. This study aimed to evaluate changes in trunk fat with GH treatment.

DESIGN

Double-blind, placebo-controlled study.

PATIENTS AND MEASUREMENTS

Sixty-one Japanese adult GH deficient patients (mean age 37 years) were randomised to either GH, titrated to 0.012 mg/kg/day, (n = 30) or placebo (n = 31) for 24 weeks. Body composition, by dual-energy X-ray absorptiometry (DXA), was evaluated at a central laboratory for trunk fat, total body fat and lean body mass. Serum lipid levels were also determined centrally.

RESULTS

At baseline, 26 (42.6%) patients had a body mass index (BMI) > or = 25 kg/m(2), the threshold for obesity-related complications for Japanese subjects. Median trunk fat mass (FM) was > or = 9.0 kg for each treatment and gender group, higher than the cut-off for increased age-adjusted risk for cardiovascular complications reported in the normal Japanese population. After 24 weeks of GH treatment, the change in percentage trunk FM was -3.4 +/- 0.6%, versus 0.4 +/- 0.6% with placebo (p < 0.001). Change in total body FM was -2.8 +/- 0.5% with GH and 0.0 +/- 0.5% with placebo, indicating that the decrease in trunk fat was more pronounced than for total body fat. Total and low density lipoprotein (LDL)-cholesterol were both significantly (p < 0.001) decreased compared with placebo. One patient discontinued due to a subdural haematoma and one had GH dose reduced due to hyperglycaemia.

CONCLUSIONS

Japanese patients with GHD have abnormal central fat accumulation, which is reduced by GH treatment over 24 weeks. This may reduce cardiovascular risk but the GH dose should be individualised to maintain IGF-I in the normal range.

Authors+Show Affiliations

Department of Clinical Molecular Medicine, Kobe University Graduate School of Medicine, Kobe, Japan. chiharak@med.kobe-u.ac.jpNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

17022857

Citation

Chihara, Kazuo, et al. "Effect of Growth Hormone Treatment On Trunk Fat Accumulation in Adult GH-deficient Japanese Patients: a Randomised, Placebo-controlled Trial." Current Medical Research and Opinion, vol. 22, no. 10, 2006, pp. 1973-9.
Chihara K, Kato Y, Takano K, et al. Effect of growth hormone treatment on trunk fat accumulation in adult GH-deficient Japanese patients: a randomised, placebo-controlled trial. Curr Med Res Opin. 2006;22(10):1973-9.
Chihara, K., Kato, Y., Takano, K., Shimatsu, A., Kohno, H., Tanaka, T., & Irie, M. (2006). Effect of growth hormone treatment on trunk fat accumulation in adult GH-deficient Japanese patients: a randomised, placebo-controlled trial. Current Medical Research and Opinion, 22(10), 1973-9.
Chihara K, et al. Effect of Growth Hormone Treatment On Trunk Fat Accumulation in Adult GH-deficient Japanese Patients: a Randomised, Placebo-controlled Trial. Curr Med Res Opin. 2006;22(10):1973-9. PubMed PMID: 17022857.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Effect of growth hormone treatment on trunk fat accumulation in adult GH-deficient Japanese patients: a randomised, placebo-controlled trial. AU - Chihara,Kazuo, AU - Kato,Yuzuru, AU - Takano,Kazue, AU - Shimatsu,Akira, AU - Kohno,Hitoshi, AU - Tanaka,Toshiaki, AU - Irie,Minoru, PY - 2006/10/7/pubmed PY - 2006/10/25/medline PY - 2006/10/7/entrez SP - 1973 EP - 9 JF - Current medical research and opinion JO - Curr Med Res Opin VL - 22 IS - 10 N2 - OBJECTIVE: Patients with growth hormone deficiency (GHD), both Japanese and Caucasian, have an abnormal body composition with pronounced abdominal obesity. This study aimed to evaluate changes in trunk fat with GH treatment. DESIGN: Double-blind, placebo-controlled study. PATIENTS AND MEASUREMENTS: Sixty-one Japanese adult GH deficient patients (mean age 37 years) were randomised to either GH, titrated to 0.012 mg/kg/day, (n = 30) or placebo (n = 31) for 24 weeks. Body composition, by dual-energy X-ray absorptiometry (DXA), was evaluated at a central laboratory for trunk fat, total body fat and lean body mass. Serum lipid levels were also determined centrally. RESULTS: At baseline, 26 (42.6%) patients had a body mass index (BMI) > or = 25 kg/m(2), the threshold for obesity-related complications for Japanese subjects. Median trunk fat mass (FM) was > or = 9.0 kg for each treatment and gender group, higher than the cut-off for increased age-adjusted risk for cardiovascular complications reported in the normal Japanese population. After 24 weeks of GH treatment, the change in percentage trunk FM was -3.4 +/- 0.6%, versus 0.4 +/- 0.6% with placebo (p < 0.001). Change in total body FM was -2.8 +/- 0.5% with GH and 0.0 +/- 0.5% with placebo, indicating that the decrease in trunk fat was more pronounced than for total body fat. Total and low density lipoprotein (LDL)-cholesterol were both significantly (p < 0.001) decreased compared with placebo. One patient discontinued due to a subdural haematoma and one had GH dose reduced due to hyperglycaemia. CONCLUSIONS: Japanese patients with GHD have abnormal central fat accumulation, which is reduced by GH treatment over 24 weeks. This may reduce cardiovascular risk but the GH dose should be individualised to maintain IGF-I in the normal range. SN - 1473-4877 UR - https://www.unboundmedicine.com/medline/citation/17022857/Effect_of_growth_hormone_treatment_on_trunk_fat_accumulation_in_adult_GH_deficient_Japanese_patients:_a_randomised_placebo_controlled_trial_ L2 - https://www.tandfonline.com/doi/full/10.1185/030079906X132460 DB - PRIME DP - Unbound Medicine ER -